Trevena, Inc. (TRVN)

Revenue by Product

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2016	FY 2015
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2016	Dec 31, 2015
Novel Medicines for Central Nervous System Disorders	3.13M
Novel Medicines for Central Nervous System Disorders Growth	-847.61%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2016	FY 2015
Period Ending	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2016	Dec 31, 2015
United States	3.13M
United States Growth	-847.61%